The two-phase protocol concept Phase 1 would use tirzepatide for active weight loss
11 In addition, GLP-1 receptor agonists have been shown to influence satiety signaling within the central nervous system, promoting feelings of fullness that can result in less caloric intake and eventual weight loss
What I do to help patients in urgent care is very rewarding, and I think it fills a huge need in healthcare today. Need a visit quickly
The characteristic changes of GLP-1 face include 4,5 : Facial volume loss, particularly in the midface Periocular hollowing and periorbital volume depletion Dermal thinning with loss of collagen and elastin fibers Decreased skin elasticity leading to redundant skin folds Accelerated appearance of aging As a result of these facial changes, GLP-1 agonist medications can result in an older, haggard and tired looking appearance
When the pharmacological appetite suppression is reduced or withdrawn, the caloric threshold required to maintain their new weight is lower than expected, but their appetite, shaped by the neurological reward pathways that GLP-1s modulate, does not stay suppressed indefinitely without ongoing treatment